Recent Articles

July 13, 2015 12:20 pm
Jae Chung, founder and president of goBalto.
There is intense pressure to speed clinical trials and restrain costs, but inefficiencies tied to complicated protocols, globalization, and paper-based methods have stalled these efforts. The current status of clinical trials has encouraged stakeholders to embrace cloud-based solutions such as clinical trial management systems (CTMS). Read more...
July 13, 2015 9:14 am
Ryan Bushey, Associate Editor
Investigating lung cancer will be the center's first endeavor. Read more...
July 9, 2015 9:13 am
Stephanie Guzowski, Editor
Resistance to antibiotics and other antimicrobials is growing worldwide, with deaths from resistant infections at about 700,000 per year, and estimated to rise to 10 million per year by 2050. Leaders in government and industry have prompted the question: Could strategic development and use of novel vaccines prolong the life span of antibiotics in the pipeline? Read more...
July 9, 2015 9:05 am
Ryan Bushey, Associate Editor
The team at Theranos plans on submitting more lab-developed tests (LDTs) for the agency to review. Read more...
July 8, 2015 9:07 am
Priyatham Salimadugu, Associate Analyst for GBI Research
The US was the top market for overall CRO deal activity with 337 deals. Read more...
July 6, 2015 3:03 pm
Yogesh Soneji, Principal, Trinity Partners
Innovation in healthcare is at a record level – but so is its cost.  The number of novel drugs approved between 2011 and 2015 was more than 40 percent higher than in the previous five years. With certain therapies approaching a $1 million-plus price tag, it’s time to ask: will innovation eventually get stifled or can companies reimagine their business models? Read more...
July 6, 2015 12:38 pm
Ryan Bushey, Associate Editor
An estimated 5,000 to 10,000 people suffer from this condition worldwide with it typically appearing in early childhood. Read more...
July 1, 2015 3:41 pm
Heather Leach, Ph.D., Immunology and Neurology Analyst, GlobalData
The most promising products are Xadago and Rytary for early and advanced patients, and Acorda’s CVT-301 for advanced patients. Read more...
June 30, 2015 4:39 pm
Ryan Bushey, Associate Editor
The company is treading in establishing the exact cost per pill. Read more...
June 30, 2015 10:04 am
Kelly L. Lightfoot, Esq., Fuerst Ittleman David & Joseph
The first step in assessing how a HCT/P will be regulated by the FDA, and whether the resulting product will require an expensive and lengthy approval process, is determining if the HCT/P is more than minimally manipulated. Read more...
Subscribe to Drug Discovery & Development